{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:43:28Z","timestamp":1783683808329,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY1184"],"award-info":[{"award-number":["2022KY1184"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jcyt.2023.04.014","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:39:04Z","timestamp":1684543144000},"page":"885-890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Peipei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcyt.2023.04.014_bib0001","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2023.04.014_bib0002","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.transci.2017.11.017","article-title":"Management of mobilization failure in 2017","volume":"56","author":"Namdaroglu","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0003","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone marrow transplantation"},{"issue":"1","key":"10.1016\/j.jcyt.2023.04.014_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21556","article-title":"Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"Moreb","year":"2018","journal-title":"Journal of clinical apheresis"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0006","article-title":"Inferior prognosis in poor mobilizing myeloma patients","volume":"59","author":"Yi\u011feno\u011flu","year":"2020","journal-title":"Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis"},{"issue":"9","key":"10.1016\/j.jcyt.2023.04.014_bib0007","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2023.04.014_bib0008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21563","article-title":"UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy","volume":"33","author":"Douglas","year":"2018","journal-title":"Journal of Clinical Apheresis"},{"issue":"2","key":"10.1016\/j.jcyt.2023.04.014_bib0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/14712598.2015.971750","article-title":"Plerixafor: what we still have to learn","volume":"15","author":"Lanza","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.jcyt.2023.04.014_bib0010","article-title":"A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost analysis","volume":"59","author":"Laszlo","year":"2020","journal-title":"Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis"},{"issue":"5","key":"10.1016\/j.jcyt.2023.04.014_bib0011","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jca.21734","article-title":"Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma","volume":"34","author":"Park","year":"2019","journal-title":"Journal of Clinical Apheresis"},{"issue":"4","key":"10.1016\/j.jcyt.2023.04.014_bib0012","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jca.21784","article-title":"Higher efficacy of intermediate dose cytarabine\u00a0+\u00a0G-CSF compared to cyclophosphamide\u00a0+\u00a0G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma","volume":"35","author":"Bogucka-Fedorczuk","year":"2020","journal-title":"Journal of Clinical Apheresis"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0013","first-page":"318","article-title":"Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies","volume":"58","author":"Callera","year":"2019","journal-title":"Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis"},{"issue":"2","key":"10.1016\/j.jcyt.2023.04.014_bib0014","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbmt.2018.09.023","article-title":"Increased efficacy of stem cell chemomobilization with intermediate-dose cytarabine plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone in patients with multiple myeloma: Results of a randomized trial","volume":"25","author":"Czerw","year":"2019","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2023.04.014_bib0015","article-title":"High efficacy of stem cell mobilization with etoposide+cytarabine plus G-CSF in patients with multiple myeloma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.04.014_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/bmt.2011.73","article-title":"Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia","volume":"47","author":"Mahindra","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2023.04.014_bib0017","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bmt.2012.216","article-title":"Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT","volume":"48","author":"Wood","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jcyt.2023.04.014_bib0018","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41409-018-0396-x","article-title":"Cytarabine\u2009+\u2009G-CSF is more effective than cyclophosphamide\u2009+\u2009G-CSF as a stem cell mobilization regimen in multiple myeloma","volume":"54","author":"Jelinek","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"15-16","key":"10.1016\/j.jcyt.2023.04.014_bib0019","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00508-017-1205-z","article-title":"Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients","volume":"129","author":"Skopec","year":"2017","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"10.1016\/j.jcyt.2023.04.014_bib0020","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14712598.2014.895809","article-title":"Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization","volume":"14","author":"Martino","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2023.04.014_bib0021","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2014.297","article-title":"Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis","volume":"50","author":"Kim","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2023.04.014_bib0022","first-page":"2891","article-title":"Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial","volume":"23","author":"Masuda","year":"2015","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0023","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2023.04.014_bib0024","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)","volume":"33","author":"Zhu","year":"2021","journal-title":"Chin J Cancer Res"},{"issue":"7","key":"10.1016\/j.jcyt.2023.04.014_bib0026","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2023.04.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720975397","article-title":"Comparison of survival between autologous and allogeneic stem cell transplantation in patients with relapsed or refractory B-Cell non-Hodgkin lymphoma: a meta-analysis","volume":"29","author":"Wang","year":"2020","journal-title":"Cell Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2023.04.014_bib0028","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41375-022-01563-8","article-title":"The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years","volume":"36","author":"Bazarbachi","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jcyt.2023.04.014_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040863","article-title":"Role of stem cell transplantation in multiple myeloma","volume":"13","author":"Devarakonda","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.jcyt.2023.04.014_bib0030","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/bmt.2009.370","article-title":"Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma","volume":"45","author":"Gertz","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2023.04.014_bib0031","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1042819031000067585","article-title":"Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation","volume":"44","author":"Gordan","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jcyt.2023.04.014_bib0032","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ajh.25672","article-title":"Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts","volume":"95","author":"Shah","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jcyt.2023.04.014_bib0033","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.jcyt.2023.04.014_bib0034","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0609.2011.01605.x","article-title":"Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells","volume":"86","author":"Basak","year":"2011","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.jcyt.2023.04.014_bib0035","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2023.04.014_bib0036","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","article-title":"Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies","volume":"18","author":"Sheppard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2023.04.014_bib0037","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0038","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jca.21885","article-title":"Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: a multicenter report by the Polish Myeloma Study Group","volume":"36","author":"Drozd-Soko\u0142owska","year":"2021","journal-title":"J Clin Apher"},{"issue":"7","key":"10.1016\/j.jcyt.2023.04.014_bib0039","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bmt.2012.269","article-title":"Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers","volume":"48","author":"Giebel","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2023.04.014_bib0040","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:50:15Z","timestamp":1761443415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1465324923001305"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.04.014","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}